CEL-SCI Corporation has announced the completion of its Breakthrough Medicine Designation application for Multikine, an investigational immunotherapy for head and neck cancer, to the Saudi Food and Drug Authority (SFDA). The application is expected to be formally submitted within the next few weeks by CEL-SCI's prospective Saudi partner, a leading pharmaceutical and healthcare company in the country. A response from the SFDA is anticipated within approximately 60 days. If granted, Multikine could become available for patient access and commercial use in Saudi Arabia by the summer of 2025. The treatment has demonstrated a significant increase in the 5-year survival rate for the target patient population.